EUVIMEDOpdag EUVIMED
Multizentrische Studie

Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage

Eugenio De Corso iD, Claudio Montuori iD, Carlotta Pipolo iD, Ignazio La Mantia iD, Ernesto Pasquini iD, Angelo Ghidini iD, Veronica Seccia iD, Giancarlo Ottaviano iD, Elena Cantone iD, Giulia Dané iD, Massimiliano Garzaro, Gian Luca Fadda iD and 18 more

Allergy · 2026-02 · 81 (2) · 388-401

DOI: 10.1111/all.70032 ↗

At a glance

Multizentrische Studie in Allergy, published online on 2025-08-30. Written by Eugenio De Corso and 29 co-authors. Institution: Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps, Rhinitis. Cited 24 times so far (Crossref); 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real‐life studies have been conducted on small patient cohorts for up to 1 year.

Methods

This ambispective, multicentric, 2‐year‐long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers.

Results

The study involved 926 patients. At 24 months, median nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino‐nasal Outcome Test‐22 (SNOT‐22), and olfaction improved from baseline (all p < 0.0001). Patients with NPS > 4, and/or SNOT‐22 > 30, and/or Sniffin’ Sticks Identification Test‐16 (SSIT‐16) < 12 at 12 months demonstrated improvements in these outcomes over the second year. Overall, 18.7% of patients extended the dupilumab interdose interval to every 4 weeks (q4w). Notably, 91.2% of patients were “good‐to‐excellent” responders based on EPOS/Euforea criteria. Given the absence of standardized definitions for disease control and remission, we proposed different sets of criteria reporting results from different scenarios. Remission analysis is clinically important as it helps define treatment success and long‐term therapeutic goals. Most adverse events were mild‐to‐moderate; 2.4% of patients discontinued treatment due to safety concerns.

Conclusions

This is the largest real‐life study evaluating dupilumab in CRSwNP over 2 years. Dupilumab showed sustained effectiveness, with progressive improvements across all clinical outcomes. Dupilumab tapering did not compromise outcomes; treatment continuation allowed meaningful clinical benefits in late responders. Two‐year rates of disease control and remission are clinically relevant, although standardized criteria to assess these outcomes are needed.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedSinusitisNasal PolypsRhinitisHumansChronic DiseaseMaleFemaleMiddle AgedTreatment OutcomeAdultAgedRemission InductionRhinosinusitis

Author keywords

CRSwNPcontroldupilumablate responselong termremission

Substances

dupilumabAntibodies, Monoclonal, Humanized

Authors and institutions

  • Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
  • Department of Head, Neck and Sensory Organs, Catholic University of the Sacred Heart, Rome, Italy.
  • Otorhinolaryngology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo Hospital, Università Degli Studi di Milano, Milan, Italy.
  • Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", ENT Section, University of Catania, Catania, Italy.
  • ENT Unit, Bellaria Hospital, Azienda USL Bologna, Bologna, Italy.
  • Otorhinolaryngology Head and Neck Surgery Department, IRCCS Arcispedale Santamaria Nuova, Reggio Emilia, Italy.

ORCID profiles: Eugenio De Corso, Claudio Montuori, Carlotta Pipolo, Ignazio La Mantia, Ernesto Pasquini, Angelo Ghidini, Veronica Seccia, Giancarlo Ottaviano, Elena Cantone, Giulia Dané, Gian Luca Fadda, Fabio Pagella, Carlo Cavaliere, Francesco Bussu, Jacopo Galli

Cite

APA

De Corso, E., Montuori, C., Pipolo, C., La Mantia, I., Pasquini, E., Ghidini, A., Seccia, V., Ottaviano, G., Cantone, E., Dané, G., Garzaro, M., Fadda, G. L., Torretta, S., Anastasi, F., Canevari, F. R. M., Pagella, F., Lucidi, D., Cavaliere, C., Pagliuca, G., …, & DUPIREAL Italian Study Group (2026). Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage. Allergy, 81(2), 388-401. https://doi.org/10.1111/all.70032

Vancouver

De Corso E, Montuori C, Pipolo C, La Mantia I, Pasquini E, Ghidini A, et al. Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage. Allergy. 2026;81(2):388-401. doi:10.1111/all.70032

BibTeX
@article{DeCorso2026,
  author = {De Corso, Eugenio and Montuori, Claudio and Pipolo, Carlotta and La Mantia, Ignazio and Pasquini, Ernesto and Ghidini, Angelo and Seccia, Veronica and Ottaviano, Giancarlo and Cantone, Elena and Dané, Giulia and Garzaro, Massimiliano and Fadda, Gian Luca and Torretta, Sara and Anastasi, Francesca and Canevari, Frank Rikki Mauritz and Pagella, Fabio and Lucidi, Daniela and Cavaliere, Carlo and Pagliuca, Giulio and Maffei, Marianna and Bussu, Francesco and Corbò, Marco and D Auria, Leandro Maria and De Maio, Gabriele and Loperfido, Antonella and Gallo, Stefania and D Agostino, Giuseppe and Giannarelli, Diana and Galli, Jacopo and DUPIREAL Italian Study Group, DUPIREAL Italian Study Group},
  title = {Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {2},
  pages = {388--401},
  doi = {10.1111/all.70032}
}
Start for free →